Phase 1, Phase 2RecruitingPriority 3 · Moderate priorityNCT04925609
Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors
Plain-language summary
This Phase 1, Phase 2 trial is comparing different first-line treatment approaches for people newly diagnosed with ALK-positive ALCL. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.
Who can join (key eligibility)
- Age 1 Year to 25 Years years
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Brigatinib (DRUG): Brigatinib is a second generation novel, orally administered, tyrosine kinase inhibitor (TKI) that potently inhibits activated variants of ALK and to a lesser extent ROS1.
- Drugs / treatments
- Brigatinib
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details